Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 7/20 | 0.39 |
| ▸ | ANPEP | P15144 | 6/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | PEPD | P12955 | 3/20 | 0.31 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16479396 | 1.00 | LAP3 (0.39) | LAP3ANPEPERAP1DNPEPSLC7A5 | |
| SCHEMBL5021048 | 1.00 | LAP3 (0.39) | LAP3ANPEPERAP1DNPEPSLC7A5 | |
| SCHEMBL16479397 | 1.00 | LAP3 (0.39) | LAP3ANPEPERAP1DNPEPSLC7A5 | |
| SCHEMBL16479398 | 1.00 | LAP3 (0.39) | LAP3ANPEPERAP1DNPEPSLC7A5 | |
| SCHEMBL2308588 | 1.00 | LAP3 (0.39) | LAP3ANPEPERAP1DNPEPSLC7A5 | |
| SCHEMBL14818460 | 0.84 | LAP3 (0.42) | LAP3ANPEPERAP1DNPEPSLC7A5 | |
| SCHEMBL14818507 | 0.84 | LAP3 (0.42) | LAP3ANPEPERAP1DNPEPSLC7A5 | |
| SCHEMBL14818474 | 0.81 | LAP3 (0.35) | LAP3ANPEPERAP1 | |
| SCHEMBL14818475 | 0.81 | LAP3 (0.35) | LAP3ANPEPERAP1 | |
| SCHEMBL14818457 | 0.79 | LAP3 (0.54) | LAP3ANPEPERAP1DNPEPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9492466-B2 | Beta-hydroxy-gamma-aminophosphonates for treating immune disorders | NUCITEC S.A. DE C.V. (MX) | 2016-11-15 | — | — | US | disclosed |
| US-20140107079-A1 | Beta-hydroxy-gamma-aminophosphonates for Treating Immune Disorders | Nucites S.A. de C.V. (MX) | 2014-04-17 | — | — | US | disclosed |
| US-8536362-B2 | β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof | NUCITEC S.A. DE C.V. (MX) | 2013-09-17 | — | — | US | disclosed |
| US-8536362-B2 | β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof | NUCITEC S.A. DE C.V. (MX) | 2013-09-17 | — | — | US | disclosed |
| US-20130079308-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | NUCITEC S.A. DE C.V. (MX) | 2013-03-28 | — | — | US | disclosed |
| US-20130079308-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | NUCITEC S.A. DE C.V. (MX) | 2013-03-28 | — | — | US | disclosed |
| US-8178515-B2 | β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof | NUCITEC S.A. DE C.V. (MX) | 2012-05-15 | — | — | US | disclosed |
| US-8178515-B2 | β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof | NUCITEC S.A. DE C.V. (MX) | 2012-05-15 | — | — | US | disclosed |
| US-20100087400-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | NUCITEC S.A. DE C.V. (MX) | 2010-04-08 | — | — | US | disclosed |
| US-20100087400-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | NUCITEC S.A. DE C.V. (MX) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107079-A1 | Beta-hydroxy-gamma-aminophosphonates for Treating Immune Disorders | IFNG, HPGDS, AASDHPPT | LAP3 661/4885ANPEP 295/4885ERAP1 223/4885 |
| US-20130079308-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | CPT1A, ACAT1, ABAT | LAP3 636/4885ANPEP 322/4885ERAP1 543/4885 |
| US-20100087400-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | CPT1A, ACAT1, ABAT | LAP3 636/4885ANPEP 322/4885ERAP1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.